Is Seres Therapeutics Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 3 Wall Street analysts covering (NASDAQ: MCRB) stock is to Buy MCRB stock.
Out of 3 analysts, 1 (33.33%) are recommending MCRB as a Strong Buy, 1 (33.33%) are recommending MCRB as a Buy, 1 (33.33%) are recommending MCRB as a Hold, 0 (0%) are recommending MCRB as a Sell, and 0 (0%) are recommending MCRB as a Strong Sell.
What is MCRB's forecast return on equity (ROE) for 2023-2026?
(NASDAQ: MCRB) forecast ROE is N/A, which is considered weak.
What is MCRB's Price Target?
According to 3 Wall Street analysts that have issued a 1 year MCRB price target, the average MCRB price target is $9.67, with the highest MCRB stock price forecast at $12.00 and the lowest MCRB stock price forecast at $7.00.
On average, Wall Street analysts predict that Seres Therapeutics's share price could reach $9.67 by Jun 26, 2024. The average Seres Therapeutics stock price prediction forecasts a potential upside of 270.38% from the current MCRB share price of $2.61.
What is MCRB's forecast return on assets (ROA) for 2023-2026?
(NASDAQ: MCRB) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.07%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.